Company / Accounts Receivable
Niagen Bioscience, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$9.7M
FY2025
5-year range
$5.2M / $9.7M
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has increased for 3 consecutive years, from $2M in FY2019 to $10M in FY2025.
Based on SEC 10-K filings.
$10M in FY2025 with a 3-year CAGR of +4.7%.
Improved from $5M to $10M over the past 4 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +4.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +4.7%, indicating consistent growth.
- Lowest accounts receivable in the period was in FY2019.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.7M | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $8.5M | +62.3% |
| FY2021 | $5.2M | - |
| FY2020 | - | - |
| FY2019 | $2.2M | -50.1% |
| FY2018 | $4.4M | -18.3% |
| FY2017 | $5.3M | -8.8% |
| FY2016 | $5.9M | +138.8% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026